Literature DB >> 27878377

Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.

Jian Ding1, Jiejin Zhang1, Xixi Wang1, Li Zhang1, Siming Jiang1, Yongsheng Yuan1, Junyi Li1, Lin Zhu1, Kezhong Zhang2.   

Abstract

The aim of our study is to examine the plasma levels of the four kinds of neurodegenerative proteins in plasma: α-syn, T-tau, P-tau181, and Aβ-42 in Parkinson's disease (PD) and to evaluate the relationship between their plasma levels and PD motor subtypes. 84 patients with PD were enrolled in our study, and finally, 73 of them were classified into the tremor-dominant subtype (TD) and the postural instability gait difficulty subtype (PIGD). Their motor performance was evaluated by a series of clinical assessments: Freezing of Gait Questionnaire (FOGQ), Timed Up and Go (TUGs), Tinetti balance, and Tinetti gait. Plasma levels of these proteins were measured by enzyme-linked immunosorbent assay (ELISA). The plasma level of α-syn was significantly higher in PD patients when compared to controls (p = 0.004), and significantly higher in the PIGD group when compared to the TD group (p = 0.03). While the plasma level of Aβ-42 was significantly lower in PD patients than in controls (p = 0.002), and significantly lower in the PIGD group than in the TD group (p = 0.05). In PD patients, the plasma level of α-syn (r = -0.355, p < 0.001) was significantly related to the severity of Tenitti Gait score, even after performing multiple linear regression (p = 0.002). While the plasma level of Aβ-42 (r = -0.261, p < 0.05) was significantly associated with the severity of PIGD score and remained correlate when performed multiple linear regression (p = 0.005). The patients with PIGD subtype are characterized with a lower level of plasma Aβ-42 and a higher plasma level of α-syn, which may be used as biomarkers for diagnosis and progression of the subtypes of PD.

Entities:  

Keywords:  Neurodegenerative proteins; Parkinson’s disease; Postural instability gait difficulty subtype; Tremor-dominant subtype

Mesh:

Substances:

Year:  2016        PMID: 27878377     DOI: 10.1007/s00702-016-1650-2

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  34 in total

1.  Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease.

Authors:  Benoit Lehallier; Laurent Essioux; Javier Gayan; Roxana Alexandridis; Tania Nikolcheva; Tony Wyss-Coray; Markus Britschgi
Journal:  JAMA Neurol       Date:  2015-12-14       Impact factor: 18.302

2.  Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease.

Authors:  Penelope G Foulds; J Douglas Mitchell; Angela Parker; Roisin Turner; Gerwyn Green; Peter Diggle; Masato Hasegawa; Mark Taylor; David Mann; David Allsop
Journal:  FASEB J       Date:  2011-08-24       Impact factor: 5.191

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

5.  Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.

Authors:  Daniela Besong-Agbo; Elias Wolf; Frank Jessen; Matthias Oechsner; Eva Hametner; Werner Poewe; Markus Reindl; Wolfgang H Oertel; Carmen Noelker; Michael Bacher; Richard Dodel
Journal:  Neurology       Date:  2012-12-19       Impact factor: 9.910

6.  Nasal inoculation with α-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine.

Authors:  Marina A Gruden; Tatiana V Davidova; Kiran Yanamandra; Valery G Kucheryanu; Ludmilla A Morozova-Roche; Vladimir V Sherstnev; Robert D E Sewell
Journal:  Behav Brain Res       Date:  2013-01-17       Impact factor: 3.332

7.  Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.

Authors:  Nour K Majbour; Nishant N Vaikath; Paolo Eusebi; Davide Chiasserini; Mustafa Ardah; Shiji Varghese; M Emdadul Haque; Takahiko Tokuda; Peggy Auinger; Paolo Calabresi; Lucilla Parnetti; Omar M A El-Agnaf
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

Review 8.  Alpha-Synuclein as a Biomarker for Parkinson's Disease.

Authors:  Anzari Atik; Tessandra Stewart; Jing Zhang
Journal:  Brain Pathol       Date:  2016-05       Impact factor: 6.508

9.  The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy.

Authors:  P H Lee; G Lee; H J Park; O Y Bang; I S Joo; K Huh
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

10.  Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease.

Authors:  Karin D van Dijk; Wesley Jongbloed; Johannes A Heijst; Charlotte E Teunissen; Henk J Groenewegen; Henk W Berendse; Wilma D J van de Berg; Robert Veerhuis
Journal:  Parkinsonism Relat Disord       Date:  2013-08-06       Impact factor: 4.891

View more
  10 in total

1.  Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis.

Authors:  Anastasia Bougea; Leonidas Stefanis; George P Paraskevas; Evangelia Emmanouilidou; Kostas Vekrelis; Elisabeth Kapaki
Journal:  Neurol Sci       Date:  2019-02-04       Impact factor: 3.307

Review 2.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

Review 3.  Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.

Authors:  Upasana Ganguly; Sukhpal Singh; Soumya Pal; Suvarna Prasad; Bimal K Agrawal; Reena V Saini; Sasanka Chakrabarti
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

4.  Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.

Authors:  Adeline Su Lyn Ng; Yi Jayne Tan; Alisa Cui Wen Yong; Seyed Ehsan Saffari; Zhonghao Lu; Ebonne Yulin Ng; Samuel Yong Ern Ng; Nicole Shuang Yu Chia; Xinyi Choi; Dede Heng; Shermyn Neo; Zheyu Xu; Nicole Chwee Har Keong; Kay Yaw Tay; Wing Lok Au; Louis Chew Seng Tan; Eng-King Tan
Journal:  Mol Neurodegener       Date:  2020-06-05       Impact factor: 14.195

5.  Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease.

Authors:  Chun-Wei Chang; Shieh-Yueh Yang; Che-Chuan Yang; Chia-Wen Chang; Yih-Ru Wu
Journal:  Front Neurol       Date:  2020-01-21       Impact factor: 4.003

Review 6.  Update on CSF Biomarkers in Parkinson's Disease.

Authors:  Eun Hae Kwon; Sabrina Tennagels; Ralf Gold; Klaus Gerwert; Léon Beyer; Lars Tönges
Journal:  Biomolecules       Date:  2022-02-18

Review 7.  Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.

Authors:  Lorenzo Barba; Federico Paolini Paoletti; Giovanni Bellomo; Lorenzo Gaetani; Steffen Halbgebauer; Patrick Oeckl; Markus Otto; Lucilla Parnetti
Journal:  Mov Disord       Date:  2022-02-05       Impact factor: 9.698

8.  Association of Plasma and Electroencephalography Markers With Motor Subtypes of Parkinson's Disease.

Authors:  Xiaoxia Yang; Zhen Li; Lipeng Bai; Xiao Shen; Fei Wang; Xiaoxuan Han; Rui Zhang; Zhuo Li; Jinghui Zhang; Mengmeng Dong; Yanlin Wang; Tingyu Cao; Shujun Zhao; Chunguang Chu; Chen Liu; Xiaodong Zhu
Journal:  Front Aging Neurosci       Date:  2022-07-12       Impact factor: 5.702

Review 9.  Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice.

Authors:  Lars Tönges; Carsten Buhmann; Stephan Klebe; Jochen Klucken; Eun Hae Kwon; Thomas Müller; David J Pedrosa; Nils Schröter; Peter Riederer; Paul Lingor
Journal:  J Neural Transm (Vienna)       Date:  2022-04-15       Impact factor: 3.850

10.  Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease.

Authors:  Chin-Hsien Lin; Huei-Chun Liu; Shieh-Yueh Yang; Kai-Chien Yang; Chau-Chung Wu; Ming-Jang Chiu
Journal:  J Clin Med       Date:  2019-10-03       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.